Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

323.18 +5.44 (+1.71%)
Streaming Delayed Price Updated: 2:24 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
61 62 Next >
News headline image
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 ↗
Via The Motley Fool
Topics Stocks
News headline image
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results ↗
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
News headline image
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
News headline image
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗
Via The Motley Fool
Topics Stocks
News headline image
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations ↗
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
News headline image
Unpacking the Latest Options Trading Trends in Amgen ↗
 
Via Benzinga
News headline image
Peering Into Amgen's Recent Short Interest ↗
 
Via Benzinga
News headline image
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation ↗
Amgen's Lumakras treatment, combined with Vectibix, is FDA-approved for KRAS G12C-mutated colorectal cancer. 
Via Benzinga
News headline image
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows ↗
Via The Motley Fool
News headline image
What Lies Ahead In 2025? Slower Growth, More Volatility ↗
As we move through 2025, the global economy and financial markets are facing a critical juncture. 
Via Talk Markets
Topics Economy Stocks / Equities
News headline image
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows. ↗
Via The Motley Fool
News headline image
3 High-Yield Dividend Stocks to Buy in 2025 ↗
Via The Motley Fool
News headline image
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
News headline image
Analyst Expectations For Amgen's Future ↗
 
Via Benzinga
News headline image
Looking At Amgen's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
UK Greenlights Amgen's Drug For Aggressive Lung Cancer In Pretreated Patients ↗
Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited treatment options. 
Via Benzinga
News headline image
Prediction: These 3 Healthcare Stocks Will Soar in 2025 ↗
Via The Motley Fool
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Via The Motley Fool
Topics Stocks
News headline image
Spotlight on Amgen: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
2 Excellent Dividend Stocks to Buy on the Dip ↗
Via The Motley Fool
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Dissecting Our Discipline ↗
All portfolio managers practice a stock-picking discipline in which they make choices. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025 ↗
In the Dow Jones Industrial Average, 28 of the 30 components pay dividends. With changes to the components in 2024, dividend yield is smaller overall. 
Via Benzinga
Topics Stocks
News headline image
3 Worst Performing Dow Jones Stocks In 2024 ↗
The Dow Jones Industrial Average will finish 2024 with a positive return. The index has climbed about 24% this year. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Schwab US Dividend Equity ETF Reverses In December: What's Going On? ↗
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
News headline image
What's Going On With Amgen Stock On Friday? ↗
Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers competitive weight loss with less frequent dosing. 
Via Benzinga
News headline image
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
News headline image
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump. ↗
Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
Via Investor's Business Daily
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.